- Home
- MYX vs SGMT Comparison
MYX vs SGMT Comparison
Compare MYX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MYX | SGMT |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.0M | 169.4M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MYX | SGMT |
|---|---|---|
| Price | $9.96 | $7.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.13 |
| AVG Volume (30 Days) | 39.5K | ★ 951.2K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $4.50 |
| 52 Week High | $9.97 | $10.06 |
Technical Indicators
Market Signals| Indicator | MYX | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 78.57 | N/A |
| Support Level | $9.89 | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.01 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 88.89 | 0.00 |
Price Performance
Historical ComparisonAbout MYX Maywood Acquisition Corp. 2 Class A Ordinary Share
Maywood Acquisition Corp 2 is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.